Drug intelligence / Profile preview

IBI188 + sintilimab

Development stage: Unknown
Lead developer: Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI188 + sintilimab is a **combination therapy** consisting of IBI188 (Letaplimab), a humanized IgG4 monoclonal antibody targeting CD47, and sintilimab, a recombinant fully human monoclonal antibody targeting programmed death-1 (PD-1). IBI188 blocks the interaction between CD47 and SIRPα on macrophages, enhancing phagocytosis and anti-tumor immune responses[1][2]. Sintilimab blocks PD-1 signaling, restoring T-cell activity and promoting anti-tumor immunity[6]. This combination is developed for the treatment of various advanced malignant tumors, including myelodysplastic syndromes (MDS), refractory acute myeloid leukemia, and solid tumors. Clinical trials have evaluated its efficacy and safety in advanced malignancies[4][7].

Other names: anti-CD47 monoclonal antibody (IBI188)anti-PD-1 monoclonal antibody (sintilimab)

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on IBI188 + sintilimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI188 + sintilimab.

Explore the full profile